3-甲基-5-(三氟甲基)苯甲酰氯 | 261952-09-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲基-5-(三氟甲基)苯甲酰氯
• 英文名称: 3-methyl-5-(trifluoromethyl)benzoyl chloride
• CAS: 261952-09-4
• 化学式: C₉H₆ClF₃O
• mdl: MFCD01631600
• 分子量: 222.594
• InChiKey: STYLTOJEHPKJDF-UHFFFAOYSA-N

物化性质

• 沸点：
  227.8±40.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  8

反应信息

• 作为反应物：
  描述：

  3-甲基-5-(三氟甲基)苯甲酰氯 在 吡啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 3-methyl-N-(2-(4-methylpiperazin-1-yl)-5-nitrophenyl)-5-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)

  摘要：

  WD repeat-containing protein 5 (WDR5) is an important component of the multiprotein complex essential for activating mixed-lineage leukemia 1 (MLL1). Rearrangement of the MLL1 gene is associated with onset and progression of acute myeloid and lymphoblastic leukemias, and targeting the WDR5-MLL1 interaction may result in new cancer therapeutics. Our previous work showed that binding of small molecule ligands to WDR5 can modulate its interaction with MLL1, suppressing MLL1 methyltransferase activity. Initial structure activity relationship studies identified N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides as potent and selective antagonists of this protein protein interaction. Guided by crystal structure data and supported by in silico library design, we optimized the scaffold by varying the C-1 benzamide and C-S substituents. This allowed us to develop the first highly potent (K-disp < 100 nM) small molecule antagonists of the WDR5-MLL1 interaction and demonstrate that N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide 16d (OICR-9429) is a potent and selective chemical probe suitable to help dissect the biological role of WDR5.

  DOI：

  10.1021/acs.jmedchem.5b01630
• 作为产物：
  描述：

  3-甲基-5-三氟甲基苯甲酸 在 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 3-甲基-5-(三氟甲基)苯甲酰氯
  参考文献：
  名称：

  Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)

  摘要：

  WD repeat-containing protein 5 (WDR5) is an important component of the multiprotein complex essential for activating mixed-lineage leukemia 1 (MLL1). Rearrangement of the MLL1 gene is associated with onset and progression of acute myeloid and lymphoblastic leukemias, and targeting the WDR5-MLL1 interaction may result in new cancer therapeutics. Our previous work showed that binding of small molecule ligands to WDR5 can modulate its interaction with MLL1, suppressing MLL1 methyltransferase activity. Initial structure activity relationship studies identified N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides as potent and selective antagonists of this protein protein interaction. Guided by crystal structure data and supported by in silico library design, we optimized the scaffold by varying the C-1 benzamide and C-S substituents. This allowed us to develop the first highly potent (K-disp < 100 nM) small molecule antagonists of the WDR5-MLL1 interaction and demonstrate that N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide 16d (OICR-9429) is a potent and selective chemical probe suitable to help dissect the biological role of WDR5.

  DOI：

  10.1021/acs.jmedchem.5b01630

文献信息

• Tetrazolones as a Carboxylic Acid Bioisosteres
  申请人：RIGEL PHARMACEUTICALS, INC.

  公开号：US20160213648A1

  公开（公告）日：2016-07-28

  The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本公开提供了包括活性剂羧基的四唑酮衍生物的化合物。本公开还涉及包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的过程。
• [EN] BIARYL INHIBITORS OF THE SODIUM CHANNEL<br/>[FR] INHIBITEURS BIARYLE DU CANAL SODIQUE
  申请人：ZALICUS PHARMACEUTICALS LTD

  公开号：WO2013131018A1

  公开（公告）日：2013-09-06

  The invention relates to compounds useful in treating conditions associated with voltage- gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns biaryl derivatives (e.g., compounds according to any of Formulas (I)-(XII) or Compounds (l)-(372) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

  该发明涉及与电压门控离子通道功能相关的化合物，特别是与钠通道活性相关的病症。更具体地说，该发明涉及联萘衍生物（例如，根据表1的任一公式（I）-（XII）或化合物（l）-（372）的化合物），这些化合物可用于治疗癫痫、癌症、疼痛、偏头痛、帕金森病、情绪障碍、精神分裂症、精神病、耳鸣、肌萎缩性侧索硬化、青光眼、缺血、痉挛性障碍、强迫症、不安腿综合征和抽动症等病症的治疗。
• BIFUNCTIONAL ORGANIC CATALYSTS
  申请人：DIXON Darren J.

  公开号：US20150298109A1

  公开（公告）日：2015-10-22

  The present invention provides a bifunctional catalyst of the formula (1): wherein: each R 1 is independently selected from an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted aralkyl group and an optionally substituted alkaryl group; Z represents a divalent organic linking moiety optionally containing one or more stereocentres; and EWG represents an electron-withdrawing group. (R 1 ) 3 P═N—Z—NH-EWG  (1)

  本发明提供了一种双功能催化剂，其化学式为（1）：其中：每个R1独立地选择自可选取代的烷基、可选取代的环烷基、可选取代的芳基、可选取代的杂环芳基、可选取代的芳基烷基和可选取代的烷基芳基；Z代表一个二价有机连接基，可选含一个或多个立体中心；EWG代表一个电子吸引基团。（R1）3P═N—Z—NH-EWG  （1）
• PROCESS FOR THE PREPARATION OF APREPITANT
  申请人：Nath Asok

  公开号：US20100004242A1

  公开（公告）日：2010-01-07

  The present invention relates to a highly pure (2R,3S)-4-benzyl-3-(4-fluorophenyl)morpholin-2-yl 3,5-bis(trifluoromethyl)benzoate of Formula II, and a process for its preparation. The present invention further provides a process for preparation of Aprepitant of Formula I or pharmaceutically acceptable salt thereof, using the highly pure compound of Formula II. The present invention also provides a process for preparation of Aprepitant of Formula I or pharmaceutically acceptable salt thereof which comprises of cyclising the compound of Formula VII at elevated temperature, in the absence of solvent.

  本发明涉及一种高度纯净的(2R,3S)-4-苄基-3-(4-氟苯基)吗啡啶-2-基3,5-双(三氟甲基)苯甲酸酯（式II），以及其制备方法。本发明还提供了一种使用式II高度纯净化合物制备式I或其药学上可接受的盐的阿普利坦的方法。本发明还提供了一种制备式I或其药学上可接受的盐的阿普利坦的方法，其中包括在无溶剂存在下，在高温下使式VII的化合物环化。
• Organic Compounds
  申请人：PORTMANN Robert

  公开号：US20110282053A1

  公开（公告）日：2011-11-17

  A process for preparing compounds of formula I or a solvate or hydrate thereof, where R, R 1 , R 2 , R 3 and R 5 have the meanings as indicated in the specification. Such compounds are useful in the treatment of a number of conditions associated with substance P and neurokinin.

  一种制备式I化合物或其溶剂化物或水合物的方法，其中R、R1、R2、R3和R5的含义如规范中所示。这些化合物在治疗与P物质和神经激肽相关的多种疾病方面具有用途。